CoChat
Sign Up
Cited by 198

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Immunotherapy in Renal Cell Carcinoma: The Future Is Now

Deleuze, Antoine, Saout, Judikaël, Dugay, Frédéric, Peyronnet, Benoit, Mathieu, Romain, Verhoest, Gregory, Bensalah, Karim, Crouzet, Laurence, Laguerre, Brigitte, Belaud-Rotureau, Marc-Antoine, Rioux-Leclercq, Nathalie, Kammerer-Jacquet, Solène-Florence·2020·International Journal of Molecular Sciences
DOI 10.3390/ijms21072532PMC PMC7177761
Open this paper in CoChat — free account

Abstract

Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21072532

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 83

  1. Siegel, 2019, Cancer statistics, CA Cancer J. Clin., 69, 7, 10.3322/caac.21551 · DOI · Paper page
  2. Ljungberg, 2011, The epidemiology of renal cell carcinoma, Eur. Urol., 60, 615, 10.1016/j.eururo.2011.06.049 · DOI
  3. Gossage, 2015, Vhl, the story of a tumour suppressor gene, Nat. Rev. Cancer, 15, 55, 10.1038/nrc3844 · DOI
  4. Akaza, 2014, Axitinib for the treatment of advanced renal cell carcinoma, Expert Opin. Pharmacother., 15, 283, 10.1517/14656566.2014.868436 · DOI
  5. Motzer, 2013, Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med., 369, 722, 10.1056/NEJMoa1303989 · DOI
  6. Choueiri, 2015, Cabozantinib versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med., 373, 1814, 10.1056/NEJMoa1510016 · DOI
  7. Rini, 2020, Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (tivo-3): A phase 3, multicentre, randomised, controlled, open-label study, Lancet Oncol., 21, 95, 10.1016/S1470-2045(19)30735-1 · DOI
  8. Moch, 2016, The 2016 who classification of tumours of the urinary system and male genital organs-part a: Renal, penile, and testicular tumours, Eur. Urol., 70, 93, 10.1016/j.eururo.2016.02.029 · DOI
  9. Argani, 2015, Mit family translocation renal cell carcinoma, Semin. Diagn. Pathol., 32, 103, 10.1053/j.semdp.2015.02.003 · DOI
  10. Malouf, 2013, Genomic heterogeneity of translocation renal cell carcinoma, Clin. Cancer Res., 19, 4673, 10.1158/1078-0432.CCR-12-3825 · DOI
  11. Malouf, 2016, Unique transcriptomic profile of collecting duct carcinomas relative to upper tract urothelial carcinomas and other kidney carcinomas, Sci. Rep., 6, 30988, 10.1038/srep30988 · DOI
  12. Carlo, 2017, Genomic characterization of renal medullary carcinoma and treatment outcomes, Clin. Genitourin. Cancer, 15, e987, 10.1016/j.clgc.2017.04.012 · DOI
  13. Chen, 2014, Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: Recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry, Am. J. Surg. Pathol., 38, 627, 10.1097/PAS.0000000000000163 · DOI
  14. Malouf, 2016, Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations, Eur. Urol., 70, 348, 10.1016/j.eururo.2016.01.051 · DOI
  15. Albiges, 2019, Updated european association of urology guidelines on renal cell carcinoma: Immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma, Eur. Urol., 76, 151, 10.1016/j.eururo.2019.05.022 · DOI
  16. Motzer, 2002, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J. Clin. Oncol., 20, 289, 10.1200/JCO.2002.20.1.289 · DOI
  17. Fyfe, 1995, Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J. Clin. Oncol., 13, 688, 10.1200/JCO.1995.13.3.688 · DOI
  18. Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med., 356, 115, 10.1056/NEJMoa065044 · DOI
  19. Leite, 2015, Pd-l1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis, Diagn. Pathol., 10, 189, 10.1186/s13000-015-0414-x · DOI
  20. Thompson, 2007, Implications of b7-h1 expression in clear cell carcinoma of the kidney for prognostication and therapy, Clin. Cancer Res., 13, 709s, 10.1158/1078-0432.CCR-06-1868 · DOI
  21. Thompson, 2007, Pd-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma, Clin. Cancer Res., 13, 1757, 10.1158/1078-0432.CCR-06-2599 · DOI · Paper page
  22. Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N. Engl. J. Med., 380, 1103, 10.1056/NEJMoa1816047 · DOI
  23. Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017 · DOI · Paper page
  24. Dunn, 2002, Cancer immunoediting: From immunosurveillance to tumor escape, Nat. Immunol., 3, 991, 10.1038/ni1102-991 · DOI · Paper page
  25. Anderson, 2016, Lag-3, tim-3, and tigit: Co-inhibitory receptors with specialized functions in immune regulation, Immunity, 44, 989, 10.1016/j.immuni.2016.05.001 · DOI · Paper page
  26. Akino, 2009, Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors, Am. J. Pathol., 175, 2657, 10.2353/ajpath.2009.090202 · DOI
  27. Edeline, 2012, Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma, Hum. Pathol., 43, 1982, 10.1016/j.humpath.2012.01.023 · DOI
  28. Dufies, 2017, Sunitinib stimulates expression of vegfc by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas, Cancer Res., 77, 1212, 10.1158/0008-5472.CAN-16-3088 · DOI
  29. Thompson, 2006, Tumor b7-h1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up, Cancer Res., 66, 3381, 10.1158/0008-5472.CAN-05-4303 · DOI · Paper page
  30. Choueiri, 2014, Pd-l1 expression in nonclear-cell renal cell carcinoma, Ann. Oncol., 25, 2178, 10.1093/annonc/mdu445 · DOI
  31. Gupta, 2019, JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: Implications for clinical management, Mod. Pathol., 32, 1344, 10.1038/s41379-019-0269-x · DOI
  32. Chevrier, 2017, An immune atlas of clear cell renal cell carcinoma, Cell, 169, 736, 10.1016/j.cell.2017.04.016 · DOI
  33. Giraldo, 2017, Tumor-infiltrating and peripheral blood t-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma, Clin. Cancer Res., 23, 4416, 10.1158/1078-0432.CCR-16-2848 · DOI
  34. Sjoberg, 2018, A minority-group of renal cell cancer patients with high infiltration of cd20 + b-cells is associated with poor prognosis, Br. J. Cancer, 119, 840, 10.1038/s41416-018-0266-8 · DOI
  35. Choueiri, 2016, Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma, Clin. Cancer Res., 22, 5461, 10.1158/1078-0432.CCR-15-2839 · DOI · Paper page
  36. Shirotake, 2019, Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report, Mol. Clin. Oncol., 10, 244
  37. Rini, 2019, Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (immotion151): A multicentre, open-label, phase 3, randomised controlled trial, Lancet, 393, 2404, 10.1016/S0140-6736(19)30723-8 · DOI
  38. Motzer, 2019, Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial, Lancet Oncol., 20, 1370, 10.1016/S1470-2045(19)30413-9 · DOI · Paper page
  39. Lalani, 2019, Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions, Eur. Urol., 75, 100, 10.1016/j.eururo.2018.10.010 · DOI
  40. Tomita, 2017, Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the checkmate 025 study, Jpn. J. Clin. Oncol., 47, 639, 10.1093/jjco/hyx049 · DOI
  41. Ravaud, 2016, Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy, N. Engl. J. Med., 375, 2246, 10.1056/NEJMoa1611406 · DOI
  42. Motzer, 2019, Nccn guidelines insights: Kidney cancer, version 2.2020, J. Natl. Compr. Cancer Netw., 17, 1278, 10.6004/jnccn.2019.0054 · DOI · Paper page
  43. Templeton, 2015, Systemic therapy for non-clear cell renal cell carcinomas: A systematic review and meta-analysis, Eur. Urol., 67, 740, 10.1016/j.eururo.2014.05.010 · DOI
  44. Koshkin, 2018, Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma, J. Immunother. Cancer, 6, 9, 10.1186/s40425-018-0319-9 · DOI
  45. Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Wang, F., Sun, J., Yang, Q., Zhang, X., and Lu, B. (2012). Tim-3 expression characterizes regulatory t cells in tumor tissues and is associated with lung cancer progression. PLoS ONE, 7. · DOI
  46. Casado, 2009, Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines, Cancer Immunol. Immunother., 58, 1517, 10.1007/s00262-009-0682-y · DOI
  47. Inamura, 2019, Relationship of b7-h3 expression in tumor cells and tumor vasculature with foxp3+ regulatory t cells in renal cell carcinoma, Cancer Manag. Res., 11, 7021, 10.2147/CMAR.S209205 · DOI
  48. Wang, 2011, Vista, a novel mouse ig superfamily ligand that negatively regulates t cell responses, J. Exp. Med., 208, 577, 10.1084/jem.20100619 · DOI
  49. Chen, 2014, Vista regulates the development of protective antitumor immunity, Cancer Res., 74, 1933, 10.1158/0008-5472.CAN-13-1506 · DOI
  50. Fos, 2008, Icos ligation recruits the p50alpha pi3k regulatory subunit to the immunological synapse, J. Immunol., 181, 1969, 10.4049/jimmunol.181.3.1969 · DOI
  51. Aspeslagh, 2016, Rationale for anti-ox40 cancer immunotherapy, Eur. J. Cancer, 52, 50, 10.1016/j.ejca.2015.08.021 · DOI
  52. Shevach, 2006, The gitr-gitrl interaction: Co-stimulation or contrasuppression of regulatory activity?, Nat. Rev. Immunol., 6, 613, 10.1038/nri1867 · DOI
  53. Ramapriyan, 2019, Altered cancer metabolism in mechanisms of immunotherapy resistance, Pharmacol. Ther., 195, 162, 10.1016/j.pharmthera.2018.11.004 · DOI
  54. Chen, 2014, Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression, Breast Cancer Res., 16, 410, 10.1186/s13058-014-0410-1 · DOI
  55. Cheong, 2018, Targeting the ido1/tdo2-kyn-ahr pathway for cancer immunotherapy—challenges and opportunities, Trends Pharmacol. Sci., 39, 307, 10.1016/j.tips.2017.11.007 · DOI
  56. Leone, 2018, Targeting adenosine for cancer immunotherapy, J. Immunother. Cancer, 6, 57, 10.1186/s40425-018-0360-8 · DOI
  57. Linnemann, 2009, Adenosine regulates cd8 t-cell priming by inhibition of membrane-proximal t-cell receptor signalling, Immunology, 128, e728, 10.1111/j.1365-2567.2009.03075.x · DOI
  58. Ananieva, 2015, Targeting amino acid metabolism in cancer growth and anti-tumor immune response, World J. Biol. Chem., 6, 281, 10.4331/wjbc.v6.i4.281 · DOI
  59. Dawson, 2012, Cancer epigenetics: From mechanism to therapy, Cell, 150, 12, 10.1016/j.cell.2012.06.013 · DOI · Paper page
  60. Pan, 2018, Recent development and clinical application of cancer vaccine: Targeting neoantigens, J. Immunol. Res., 2018, 4325874, 10.1155/2018/4325874 · DOI
  61. Li, 2020, Caix-specific car-t cells and sunitinib show synergistic effects against metastatic renal cancer models, J. Immunother., 43, 16, 10.1097/CJI.0000000000000301 · DOI
  62. Heng, 2013, External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: A population-based study, Lancet Oncol., 14, 141, 10.1016/S1470-2045(12)70559-4 · DOI
  63. Kroeger, 2013, Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma, Cancer, 119, 1547, 10.1002/cncr.27947 · DOI
  64. Kammerer-Jacquet, S.F., Deleuze, A., Saout, J., Mathieu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud-Rotureau, M.A., Bensalah, K., and Rioux-Leclercq, N. (2019). Targeting the pd-1/pd-l1 pathway in renal cell carcinoma. Int. J. Mol. Sci., 20. · DOI
  65. Seeber, 2018, High ido-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma, Cancer Sci., 109, 1583, 10.1111/cas.13560 · DOI
  66. Beuselinck, 2015, Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting, Clin. Cancer Res., 21, 1329, 10.1158/1078-0432.CCR-14-1128 · DOI
  67. Hakimi, 2019, Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer—data from a randomized phase iii trial, Cancer Discov., 9, 510, 10.1158/2159-8290.CD-18-0957 · DOI
  68. McDermott, 2018, Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, Nat. Med., 24, 749, 10.1038/s41591-018-0053-3 · DOI · Paper page
  69. Joseph, 2015, Pd-1 and pd-l1 expression in renal cell carcinoma with sarcomatoid differentiation, Cancer Immunol. Res., 3, 1303, 10.1158/2326-6066.CIR-15-0150 · DOI
  70. Kamoun, 2019, A consensus molecular classification of muscle-invasive bladder cancer, Eur. Urol., 77, 420, 10.1016/j.eururo.2019.09.006 · DOI · Paper page
  71. Miao, 2016, Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups, Cancer Immunol. Res., 4, 820, 10.1158/2326-6066.CIR-16-0110 · DOI
  72. Dudley, 2016, Microsatellite instability as a biomarker for pd-1 blockade, Clin. Cancer Res., 22, 813, 10.1158/1078-0432.CCR-15-1678 · DOI
  73. Becht, 2016, Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression, Genome Biol., 17, 218, 10.1186/s13059-016-1070-5 · DOI
  74. Gerlinger, 2015, Intratumour heterogeneity in urologic cancers: From molecular evidence to clinical implications, Eur. Urol., 67, 729, 10.1016/j.eururo.2014.04.014 · DOI
  75. Suva, 2019, Single-cell rna sequencing in cancer: Lessons learned and emerging challenges, Mol. Cell, 75, 7, 10.1016/j.molcel.2019.05.003 · DOI
  76. Roelants, C., Pillet, C., Franquet, Q., Sarrazin, C., Peilleron, N., Giacosa, S., Guyon, L., Fontanell, A., Fiard, G., and Long, J.A. (2020). Ex-vivo treatment of tumor tissue slices as a predictive preclinical method to evaluate targeted therapies for patients with renal carcinoma. Cancers (Basel), 12. · DOI
  77. Meijer, 2017, Ex vivo tumor culture systems for functional drug testing and therapy response prediction, Future Sci. OA, 3, FSO190, 10.4155/fsoa-2017-0003 · DOI
  78. Seo, 2019, Mobilization of cd8( + ) t cells via cxcr4 blockade facilitates pd-1 checkpoint therapy in human pancreatic cancer, Clin. Cancer Res., 25, 3934, 10.1158/1078-0432.CCR-19-0081 · DOI
  79. Bensch, 2018, (89)zr-atezolizumab imaging as a non-invasive approach to assess clinical response to pd-l1 blockade in cancer, Nat. Med., 24, 1852, 10.1038/s41591-018-0255-8 · DOI
  80. Gradilone, 2011, Circulating tumor cells and “suspicious objects” evaluated through cellsearch(r) in metastatic renal cell carcinoma, Anticancer. Res., 31, 4219
  81. He, 2014, Epithelial-to-mesenchymal transition in renal neoplasms, Adv. Anat. Pathol., 21, 174, 10.1097/PAP.0000000000000018 · DOI
  82. Liu, 2016, Combined cell surface carbonic anhydrase 9 and cd147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients, Oncotarget, 7, 59877, 10.18632/oncotarget.10979 · DOI
  83. Santoni, 2019, Circulating tumor cells in renal cell carcinoma: Recent findings and future challenges, Front. Oncol., 9, 228, 10.3389/fonc.2019.00228 · DOI

Cited by

Sorted by citations

See all 198

Metadata

Authors
Deleuze, A., Saout, J., Dugay, F., Peyronnet, B., Mathieu, R., Verhoest, G., Bensalah, K., Crouzet, L., Laguerre, B., Belaud-Rotureau, M.-A., Rioux-Leclercq, N., & Kammerer-Jacquet, S.-F.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-04-05
Volume
21
Issue
7
Pages
2532
ISSN
1422-0067
DOI
10.3390/ijms21072532
PMC
PMC7177761
Cited by
198
References
14
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review